Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 15:66:128724.
doi: 10.1016/j.bmcl.2022.128724. Epub 2022 Apr 8.

Efficiency of bis-amidate phosphonate prodrugs

Nicholas A Lentini  1 , Xueting Huang  2 , Megan A Schladetsch  2 , Chia-Hung Christine Hsiao  2 , David F Wiemer  3 , Andrew J Wiemer  4
Affiliations

Efficiency of bis-amidate phosphonate prodrugs

Nicholas A Lentini et al. Bioorg Med Chem Lett. .

Abstract

Bis-amidate derivatives have been viewed as attractive phosphonate prodrug forms because of their straightforward synthesis, lack of phosphorus stereochemistry, plasma stability and nontoxic amino acid metabolites. However, the efficiency of bis-amidate prodrug forms is unclear, as prior studies on this class of prodrugs have not evaluated their activation kinetics. Here, we synthetized a small panel of bis-amidate prodrugs of butyrophilin ligands as potential immunotherapy agents. These compounds were examined relative to other prodrug forms delivering the same payload for their stability in plasma and cell lysate, their ability to stimulate T cell proliferation in human PBMCs, and their activation kinetics in a leukemia co-culture model of T cell cytokine production. The bis-amidate prodrugs demonstrate high plasma stability and improved cellular phosphoantigen activity relative to the free phosphonic acid. However, the efficiency of bis-amidate activation is low relative to other prodrugs that contain at least one ester such as aryl-amidate, aryl-acyloxyalkyl ester, and bis-acyloxyalkyl ester forms. Therefore, bis-amidate prodrugs do not drive rapid cellular payload accumulation and they would be more useful for payloads in which slower, sustained-release kinetics are preferred.

Keywords: Butyrophilin; Isoprenoid; Ligand; Phosphoantigen; Phosphonamidate prodrug.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Natural phosphoantigens, a synthetic analog, and various prodrug forms.
HMBPP (1) is the prototypical natural phosphoantigen (pAg). IPP (2) and DMAPP (3) are ubiquitous but weaker natural phosphoantigens. C-HMBP (4) is a synthetic analog of HMBPP (1). Various prodrug forms of C-HMBP (5-8) designed to improve its potency, including bis-amidates (8, this work).
Figure 2.
Figure 2.. Stimulation of human γδ T cell cytokine production by compound-loaded K562 cells.
K562 cells were loaded with test compounds 16 and 17, washed, then exposed to γδ T cells. The amount of interferon γ produced by the T cells was quantified by ELISA (n=3).
Scheme 1.
Scheme 1.. Synthesis of bis-amidates 11-17.
Reagents and conditions: a) TMSBr, pyridine, 0 °C to RT, overnight; b) amino acid ester hydrochloride salt, PPh3, 2,2′-dithiodipyridine, pyridine, 60 °C, overnight; c) SeO2, 70% aqueous t-BuOOH, pyridine, methanol, 0 °C to RT, overnight.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG, The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011, 49 (1), 20–33. - PubMed
    1. Wiemer AJ; Wiemer DF, Prodrugs of phosphonates and phosphates: crossing the membrane barrier. Top. Curr. Chem 2015, 360, 115–60. - PMC - PubMed
    1. Jansa P; Baszczynski O; Dracinsky M; Votruba I; Zidek Z; Bahador G; Stepan G; Cihlar T; Mackman R; Holy A; Janeba Z, A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. Eur. J. Med. Chem 2011, 46 (9), 3748–54. - PubMed
    1. Cesnek M; Jansa P; Smidkova M; Mertlikova-Kaiserova H; Dracinsky M; Brust TF; Pavek P; Trejtnar F; Watts VJ; Janeba Z, Bisamidate Prodrugs of 2-Substituted 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA, adefovir) as Selective Inhibitors of Adenylate Cyclase Toxin from Bordetella pertussis. ChemMedChem 2015, 10 (8), 1351–64. - PubMed
    1. Houot R; Schultz LM; Marabelle A; Kohrt H, T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition. Cancer immunology research 2015, 3 (10), 1115–22. - PubMed

Publication types

LinkOut - more resources